Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse

Hee Jun Kim, Sung Gwe Ahn, Hak Min Lee, Jong Tae Park, Kyunghwa Han, Seung Ah Lee, Joon Jeong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We investigated the relationships between metastasis-free interval (MFI) and tumor characteristics, and assessed the prognostic value of MFI for survival after metastasis in patients with metastatic breast cancer. Furthermore, we compared MFI among the subtypes. Methods: We identified 335 patients with postoperative tumor recurrence at distant site(s). All patients underwent curative resection and had a MFI of at least 6 months. MFI was categorized as short (<2 years), intermediate (≥2 years and <5 years), or long (≥5 years). Overall survival after metastasis (OSM) was estimated. Results: Patients with a shorter MFI were younger, more likely to have initial metastasis to visceral organs, and had a larger tumor with a higher stage and grade as well as a higher rate of nodal involvement at initial diagnosis. Among 136 patients with known disease subtypes, shorter MFI was associated with the triple-negative subtype while longer MFI was associated with the hormone receptor-positive/human epidermal growth factor receptor 2 negative subtype. Mortality after metastasis declined sharply with increasing MFI up to approximately 2 years, and continued gradually declining between 2 and 5 years. An MFI longer than 5 years did not add any survival benefit. MFI was a significant prognostic factor for OSM independent of nodal status, stage, metastatic site, and hormone receptor status of the metastasized cancer. Conclusion: MFI is closely related to biological characteristics of both primary tumors and their metastases, and has a prognostic value for survival after metastasis. We therefore suggest investigation into treatments targeting improvement of MFI as a potential novel strategy.

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalJournal of Breast Cancer
Volume18
Issue number4
DOIs
Publication statusPublished - 2015 Dec

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Recurrence
Neoplasms
Survival
Hormones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Hee Jun ; Ahn, Sung Gwe ; Lee, Hak Min ; Park, Jong Tae ; Han, Kyunghwa ; Lee, Seung Ah ; Jeong, Joon. / Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse. In: Journal of Breast Cancer. 2015 ; Vol. 18, No. 4. pp. 371-377.
@article{c62a4f91ded944088901fdc1d3b364cf,
title = "Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse",
abstract = "Purpose: We investigated the relationships between metastasis-free interval (MFI) and tumor characteristics, and assessed the prognostic value of MFI for survival after metastasis in patients with metastatic breast cancer. Furthermore, we compared MFI among the subtypes. Methods: We identified 335 patients with postoperative tumor recurrence at distant site(s). All patients underwent curative resection and had a MFI of at least 6 months. MFI was categorized as short (<2 years), intermediate (≥2 years and <5 years), or long (≥5 years). Overall survival after metastasis (OSM) was estimated. Results: Patients with a shorter MFI were younger, more likely to have initial metastasis to visceral organs, and had a larger tumor with a higher stage and grade as well as a higher rate of nodal involvement at initial diagnosis. Among 136 patients with known disease subtypes, shorter MFI was associated with the triple-negative subtype while longer MFI was associated with the hormone receptor-positive/human epidermal growth factor receptor 2 negative subtype. Mortality after metastasis declined sharply with increasing MFI up to approximately 2 years, and continued gradually declining between 2 and 5 years. An MFI longer than 5 years did not add any survival benefit. MFI was a significant prognostic factor for OSM independent of nodal status, stage, metastatic site, and hormone receptor status of the metastasized cancer. Conclusion: MFI is closely related to biological characteristics of both primary tumors and their metastases, and has a prognostic value for survival after metastasis. We therefore suggest investigation into treatments targeting improvement of MFI as a potential novel strategy.",
author = "Kim, {Hee Jun} and Ahn, {Sung Gwe} and Lee, {Hak Min} and Park, {Jong Tae} and Kyunghwa Han and Lee, {Seung Ah} and Joon Jeong",
year = "2015",
month = "12",
doi = "10.4048/jbc.2015.18.4.371",
language = "English",
volume = "18",
pages = "371--377",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "4",

}

Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse. / Kim, Hee Jun; Ahn, Sung Gwe; Lee, Hak Min; Park, Jong Tae; Han, Kyunghwa; Lee, Seung Ah; Jeong, Joon.

In: Journal of Breast Cancer, Vol. 18, No. 4, 12.2015, p. 371-377.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metastasis-free interval is closely related to tumor characteristics and has prognostic value in breast cancer patients with distant relapse

AU - Kim, Hee Jun

AU - Ahn, Sung Gwe

AU - Lee, Hak Min

AU - Park, Jong Tae

AU - Han, Kyunghwa

AU - Lee, Seung Ah

AU - Jeong, Joon

PY - 2015/12

Y1 - 2015/12

N2 - Purpose: We investigated the relationships between metastasis-free interval (MFI) and tumor characteristics, and assessed the prognostic value of MFI for survival after metastasis in patients with metastatic breast cancer. Furthermore, we compared MFI among the subtypes. Methods: We identified 335 patients with postoperative tumor recurrence at distant site(s). All patients underwent curative resection and had a MFI of at least 6 months. MFI was categorized as short (<2 years), intermediate (≥2 years and <5 years), or long (≥5 years). Overall survival after metastasis (OSM) was estimated. Results: Patients with a shorter MFI were younger, more likely to have initial metastasis to visceral organs, and had a larger tumor with a higher stage and grade as well as a higher rate of nodal involvement at initial diagnosis. Among 136 patients with known disease subtypes, shorter MFI was associated with the triple-negative subtype while longer MFI was associated with the hormone receptor-positive/human epidermal growth factor receptor 2 negative subtype. Mortality after metastasis declined sharply with increasing MFI up to approximately 2 years, and continued gradually declining between 2 and 5 years. An MFI longer than 5 years did not add any survival benefit. MFI was a significant prognostic factor for OSM independent of nodal status, stage, metastatic site, and hormone receptor status of the metastasized cancer. Conclusion: MFI is closely related to biological characteristics of both primary tumors and their metastases, and has a prognostic value for survival after metastasis. We therefore suggest investigation into treatments targeting improvement of MFI as a potential novel strategy.

AB - Purpose: We investigated the relationships between metastasis-free interval (MFI) and tumor characteristics, and assessed the prognostic value of MFI for survival after metastasis in patients with metastatic breast cancer. Furthermore, we compared MFI among the subtypes. Methods: We identified 335 patients with postoperative tumor recurrence at distant site(s). All patients underwent curative resection and had a MFI of at least 6 months. MFI was categorized as short (<2 years), intermediate (≥2 years and <5 years), or long (≥5 years). Overall survival after metastasis (OSM) was estimated. Results: Patients with a shorter MFI were younger, more likely to have initial metastasis to visceral organs, and had a larger tumor with a higher stage and grade as well as a higher rate of nodal involvement at initial diagnosis. Among 136 patients with known disease subtypes, shorter MFI was associated with the triple-negative subtype while longer MFI was associated with the hormone receptor-positive/human epidermal growth factor receptor 2 negative subtype. Mortality after metastasis declined sharply with increasing MFI up to approximately 2 years, and continued gradually declining between 2 and 5 years. An MFI longer than 5 years did not add any survival benefit. MFI was a significant prognostic factor for OSM independent of nodal status, stage, metastatic site, and hormone receptor status of the metastasized cancer. Conclusion: MFI is closely related to biological characteristics of both primary tumors and their metastases, and has a prognostic value for survival after metastasis. We therefore suggest investigation into treatments targeting improvement of MFI as a potential novel strategy.

UR - http://www.scopus.com/inward/record.url?scp=84957717856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957717856&partnerID=8YFLogxK

U2 - 10.4048/jbc.2015.18.4.371

DO - 10.4048/jbc.2015.18.4.371

M3 - Article

AN - SCOPUS:84957717856

VL - 18

SP - 371

EP - 377

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 4

ER -